Modulation of macrophage antimicrobial mechanisms by pathogenic mycobacteria
- PMID: 16920493
- DOI: 10.1016/j.imbio.2006.06.004
Modulation of macrophage antimicrobial mechanisms by pathogenic mycobacteria
Abstract
Tuberculosis remained a mysterious disease until Koch was able to demonstrate in the late 1800s that it was caused by a bacterium spread by aerosols, Mycobacterium tuberculosis. Today, tuberculosis still is a major health problem causing approximately 2 million deaths annually with about one third of the world's population being latently infected with M. tuberculosis. The secret of success for M. tuberculosis lies in its ability to persist inside host cells, the macrophages. Whereas macrophages are designed to destroy any incoming microbe, pathogenic mycobacteria have evolved strategies to survive within macrophages by preventing phagosome-lysosome fusion, thereby creating a niche that allows them to persist within an otherwise hostile environment. In this contribution, we discuss recent advances in our understanding of the interplay between the host and this pathogen that lead to survival of mycobacteria within macrophages.
Similar articles
-
The Trojan horse: survival tactics of pathogenic mycobacteria in macrophages.Trends Cell Biol. 2005 May;15(5):269-76. doi: 10.1016/j.tcb.2005.03.009. Trends Cell Biol. 2005. PMID: 15866031 Review.
-
Hijacking the host: survival of pathogenic mycobacteria inside macrophages.Trends Microbiol. 2002 Mar;10(3):142-6. doi: 10.1016/s0966-842x(02)02305-3. Trends Microbiol. 2002. PMID: 11864824
-
Mycobacterial manipulation of vacuolar sorting.Cell Microbiol. 2008 Dec;10(12):2408-15. doi: 10.1111/j.1462-5822.2008.01239.x. Epub 2008 Sep 8. Cell Microbiol. 2008. PMID: 18783482 Review.
-
The many niches and strategies used by pathogenic mycobacteria for survival within host macrophages.Immunobiology. 2009;214(7):526-42. doi: 10.1016/j.imbio.2008.12.005. Epub 2009 Mar 3. Immunobiology. 2009. PMID: 19261352 Review.
-
Battle for survival: interplay between pathogenic mycobacteria and the host immune system.Discov Med. 2006 Apr;6(32):82-6. Discov Med. 2006. PMID: 17234131
Cited by
-
Nanotechnology-Based Approach in Tuberculosis Treatment.Tuberc Res Treat. 2017;2017:4920209. doi: 10.1155/2017/4920209. Epub 2017 Jan 22. Tuberc Res Treat. 2017. PMID: 28210505 Free PMC article. Review.
-
Mycobacterium tuberculosis Requires Cholesterol Oxidase to Disrupt TLR2 Signalling in Human Macrophages.Mediators Inflamm. 2019 Dec 1;2019:2373791. doi: 10.1155/2019/2373791. eCollection 2019. Mediators Inflamm. 2019. PMID: 31871425 Free PMC article.
-
Characterizing the Mycobacterium tuberculosis Rv2707 protein and determining its sequences which specifically bind to two human cell lines.Protein Sci. 2008 Feb;17(2):342-51. doi: 10.1110/ps.073083308. Epub 2007 Dec 20. Protein Sci. 2008. PMID: 18096644 Free PMC article.
-
Mycobacteria and innate cells: critical encounter for immunogenicity.J Biosci. 2008 Mar;33(1):137-44. doi: 10.1007/s12038-008-0029-4. J Biosci. 2008. PMID: 18376078 Review.
-
The Macrophage Response to Mycobacterium tuberculosis and Opportunities for Autophagy Inducing Nanomedicines for Tuberculosis Therapy.Front Cell Infect Microbiol. 2021 Feb 8;10:618414. doi: 10.3389/fcimb.2020.618414. eCollection 2020. Front Cell Infect Microbiol. 2021. PMID: 33628745 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources